



UNITED STATES PATENT AND TRADEMARK OFFICE

ga
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.				
10/551,574	10/03/2005	Nicholas D. P. Cosford	MS0037YP	3830				
210 MERCK AND CO., INC P O BOX 2000 RAHWAY, NJ 07065-0907	7590 09/13/2007		<table border="1"><tr><td colspan="2">EXAMINER</td></tr><tr><td colspan="2">YOUNG, SHAWQUIA</td></tr></table>		EXAMINER		YOUNG, SHAWQUIA	
EXAMINER								
YOUNG, SHAWQUIA								
			<table border="1"><tr><td>ART UNIT</td><td>PAPER NUMBER</td></tr><tr><td>1626</td><td></td></tr></table>	ART UNIT	PAPER NUMBER	1626		
ART UNIT	PAPER NUMBER							
1626								
			<table border="1"><tr><td>MAIL DATE</td><td>DELIVERY MODE</td></tr><tr><td>09/13/2007</td><td>PAPER</td></tr></table>	MAIL DATE	DELIVERY MODE	09/13/2007	PAPER	
MAIL DATE	DELIVERY MODE							
09/13/2007	PAPER							

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/551,574

Applicant(s)

COSFORD, ET AL

Examiner

Shawquia Young

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 August 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 1-14 is/are allowed.
- 6) ☒ Claim(s) 15-18 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>10/3/05</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 1-18 are currently pending in the instant application.

I. *Priority*

The instant application is a 371 of PCT/US04/09845, filed on March 31, 2004 and claims benefit of US Provisional Application 60/460,085, filed on April 4, 2003..

II. *Information Disclosure Statement*

The information disclosure statement (IDS) submitted on October 3, 2005 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.

III. *Restriction/Election*

A. Election: Applicant's Response

Applicants' election with traverse of Group I in the reply filed on August 3, 2007 is acknowledged. The traversal is on the ground(s) that: (1) there is sufficient structural similarity among the compounds recited in claim 11 to present and examine this subject matter in a single application.

All of the Applicants' arguments have been considered but have not been found persuasive. It is pointed out that the restriction requirement is made under 35 U.S.C. 121. 35 U.S.C. 121 gives the Commissioner (Director) the authority to restrict applications to several claimed inventions when those inventions are found to be independent and distinct. The Examiner has indicated that more than one independent and distinct invention is claimed in this application and has restricted the claimed

Art Unit: 1626

subject matter accordingly.

Applicants argue that the species recited in claim 11 share numerous common structural features. Applicants further argue that there is sufficient structural similarity among the compounds recited in claim 11 to present and examine this subject matter in a single application. However, the Examiner wants to point out that the compounds listed in claim 11 are classified in various subclasses in class 546 and are structurally different compounds thus resulting in different activity.

The Restriction Requirement detailed the reasons for restriction between the groups. Different search considerations are involved (i.e., class/subclass searches, databases searches, etc.) for each of the groups listed. The inventions are classified into various subclasses in classes 514, 544, 546 and 548. However, each Class 514, 544, 546 and 548 encompasses numerous patents and published applications. For instance, Class 514 contained 165,171 patents and published applications. Therefore it would constitute a burden on the Examiner and the Patent Office's resources to examine the instant application in its entirety.

Applicants also argue that the inconsistent positions taken by successive Examiners on the referenced patent application have resulted in piecemeal examination and several months delay. The Examiner wants to point out that the positions taken by the current Examiner and the previous Examiner on the instant Applications are the same. Both Examiners agree that the instant claims lack unity of invention. The Examiner currently assigned to the instant application attempted to search the group elected by Applicants in the Remarks filed on April 9, 2007 but the group covered vast

Art Unit: 1626

subject matter and the Examiner was unable to search it. Therefore, the Examiner sent out a supplemental Restriction Requirement and defined groups that did not cover vast subject matter and could be searched. A supplemental Restriction Requirement is not considered piecemeal examination (See MPEP 707.07 (g)) but is considered proper if the claims lack unity of invention and there is a search burden. As far as more than three months having elapsed between restriction requirements, the Examiner wants to explain that Examiners examine cases in the order that they receive cases.

In addition, the Examiner has decided to rejoin the method of use claims 15-18 (in-part) and examine the method claims (Group VIII) with Group I.

Subject matter not encompassed by elected Group I and the related method claims 15-18 (in-part) Group VIII are withdrawn from further consideration pursuant to 37 CFR 1.142 (b), as being drawn to nonelected inventions.

IV. Rejections

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 15-18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to

Art Unit: 1626

which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In *In re Wands*, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. § 112, first paragraph, have been described. They are:

1. the nature of the invention,
2. the state of the prior art,
3. the predictability or lack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of the skill in the art.

The nature of the invention

Applicants are claiming the use of the compound of formula I for the preparation of a medicament useful in the treatment of pain disorders, extrapyramidal motor function disorders, anxiety disorders, Parkinson's disease, depression, epilepsy, cognitive disfunction, drug addiction, circadian rhythm and sleep disorders, obesity, etc.

See, for example, instant claims 15-18.

The state of the prior art and the predictability or lack thereof in the art

The state of the prior art is that Alzheimer's disease, for example, remain highly

Art Unit: 1626

unpredictable. Enablement for the scope of treating pain disorders, extrapyramidal motor function disorders, anxiety disorder, dementia, Alzheimer's disease, etc. is not present in the specification. .

Furthermore, there is a vast range of causes for the problem and biochemical pathways that mediate various diseases encompassed by Applicants' claims. There is no common mechanism by which all, or even most, of the claimed disorders arise and one treatment cannot be used to treat all of the claimed diseases or disorders.

Applicants' claims are therefore drawn to a medicament useful for treating Alzheimer's disease. It is the state of the art that there is no known cure or prevention for Alzheimer's disease and that there are only four medications available in the United States available to temporarily slow the early stages of Alzheimer's disease. The current drugs for the treatment of Alzheimer's disease, Aricept, Exelon, Reminyl and Cognex, treat early stages of Alzheimer's disease by delaying the breakdown of acetylcholine. Memantine, which blocks excess amounts of glutamate treats late stage Alzheimer's disease.

(<[URL:http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html](http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html)>.)

In addition, Layzer, Cecil Textbook of Medicine (article enclosed), states that "some degenerative diseases are difficult to classify because they involve multiple anatomic locations" (see page 2050). Alzheimer's disease has traditionally been very difficult or impossible to prevent or even to treat effectively with chemotherapeutic agents (See e.g., the Cecil Textbook of Medicine, 20th edition (1996), Vol. 2, page

Art Unit: 1626

1994).

Applicants' claims are also drawn to a medicament useful for treating dementia. Dementia is the progressive decline in cognitive function due to damage or disease in the brain beyond what might be expected from normal aging. Symptoms of dementia can be classified as either reversible or irreversible depending upon the etiology of the disease. Dementia can be caused by various types of conditions or diseases, such as Alzheimer's disease, Binswanger's disease, Pick's disease, Parkinson's disease, etc. It is known (see [URL:http://en.wikipedia.org/wiki/Dementia](http://en.wikipedia.org/wiki/Dementia)) that less than 5% of a sample of dementia cases have a potentially treatable cause that include hypothyroidism, vitamin B1 deficiency, depressive pseudodementia, etc. Except for the treatable types of dementia, there is no cure to the illness. There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.

The amount of direction or guidance present and the presence or absence of working examples

There is no evidence of record, which would enable the skilled artisan in the identification of the people who have the potential of becoming afflicted with the numerous diseases or disorders claimed herein. That a single class of compounds can be used to treat or control all diseases embraced by the claims is an incredible finding for which Applicants have not provided supporting evidence. Applicants have not

Art Unit: 1626

provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical use for treating or controlling any or all conditions by administering the instant claimed compounds.

Test assays and procedure are provided in the specification on page 32 for calcium flux assays and on pages 32-33 phosphatidylinositol hydrolysis assays.

Receptor activity is generally unpredictable and the data provided is insufficient for one of ordinary skill in the art in order to extrapolate to the other compounds of the claims. It is inconceivable as to how the claimed compounds can treat the extremely difficult diseases embraced by the instant claims.

Applicants have not provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical use of the instant compounds. Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, "the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved." See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

The breadth of the claims

The breadth of the claims is a use of the compound of formula I for the preparation of a medicament useful in the treatment of pain disorders, extrapyramidal motor function disorders, anxiety disorders, Parkinson's disease, depression, epilepsy, cognitive dysfunction, drug addiction, circadian rhythm and sleep disorders, obesity, depression, bipolar disorder, psychosis, Alzheimer's disease, schizophrenia, panic, etc.

The quantity of experimentation needed

The nature of the pharmaceutical arts is that it involves screening in vitro and in vivo to determine which compounds exhibit the desired pharmacological activities for each of the diseases and disorders instantly claimed. The quantity of experimentation needed would be undue when faced with the lack of direction and guidance present in the instant specification in regards to testing all diseases and disorders generically embraced in the claim language, and when faced with the unpredictability of the pharmaceutical art. Thus, factors such as "sufficient working examples", "the level of skill in the art" and predictability, etc. have been demonstrated to be sufficiently lacking in the instant case for the instant method claims.

The level of the skill in the art

Even though the level of skill in the pharmaceutical art is very high, based on the unpredictable nature of the invention and state of the prior art and lack of guidance and direction, one skilled in the art could not use the claimed invention without undue experimentation.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 15-18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The phrase "Use of a compound..." is written in improper format because a "use" can only be properly claimed as a process or method. It is suggested that applicant amend the claims by rewriting the claims as a process or method, i.e. "a method of preparing..."

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 15-18 are rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps involve the essential synthetic steps that are necessary in preparing a medicament for the treatment of the various diseases listed in claims 15-18. It is suggested that the applicant add the necessary steps of preparing a medicament to the instant claim.

Claims 15-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The term "medicament" is not defined or used in the specification to know what is encompassed by the term. It is unclear if Applicants are referring to a pharmaceutical composition, kit, etc. by the term "medicament". Therefore, the claims are indefinite.

Claim 15 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 15 recites the broad recitation extrapyramidal motor function disorders and the claim also recites Parkinson's disease which is the narrower statement of the range/limitation.

V. Objections

Claim Objection-Non Elected Subject Matter

Claims 1-18 are objected to as containing non-elected subject matter. To overcome this objection, Applicant should submit an amendment deleting the non-elected subject matter.


Art Unit: 1626


VI. Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Young whose telephone number is 571-272-9043. The examiner can normally be reached on 6:30 AM-3:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph M^cKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Shawquia Young
Patent Examiner
Art Unit 1626, Group 1620
Technology Center 1600


REBECCA ANDERSON
PATENT EXAMINER

 Joseph M^cKane
Supervisory Patent Examiner
Art Unit 1626, Group 1620
Technology Center 1600